The cost-effectiveness of different chemotherapy strategies for patients with poor prognosis advanced colorectal cancer (MRC FOCUS)

Value in Health

Volumn 15, Issue 1, 2012, Pages 22-31

  Manca, Andrea ^a   Asseburg, Christian ^b   Bravo Vergel, Yolanda ^c   Seymour, Matt T ^d   Meade, Angela ^e   Stephens, Richard ^e   Parmar, Mahesh ^e   Sculpher, Mark J ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c Independent Consultant   (Spain)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

advanced colorectal cancer; cost effectiveness; FOCUS trial; irinotecan; oxaliplatin

Indexed keywords

CAPECITABINE; DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; GRANISETRON; HEPARIN; IRINOTECAN; MITOMYCIN C; OXALIPLATIN;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL PROTOCOL; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG TREATMENT FAILURE; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MONTE CARLO METHOD; PRIORITY JOURNAL; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; STATISTICAL MODEL; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; FLUOROURACIL; GREAT BRITAIN; HUMANS; MARKOV CHAINS; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; STATE MEDICINE; SURVIVAL ANALYSIS;

EID: 84856004318     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2011.07.008     Document Type: Article

References (46)

1. Office for National Statistics Statistical publication notice - cancer incidence (2005) 2008 ISD http://www.wales.nhs.uk/sites3/page.cfm?orgid= 242&pid=18140 [Accessed May 6, 2009]
2. Welsh Cancer Intelligence and Surveillance Unit Cancer incidence in Wales 19922001 http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgId=242&id=18843 2005 [Accessed August 10, 2011]
3. Centre for Review and Dissemination The management of colorectal cancer 1997 Centre for Review and Dissemination, The University of York York, UK [Contract No.: 6]
4. P. Boyle, J.S. Langman ABC of colorectal cancer: epidemiology BMJ 321 2004 805 808
5. P. Ragnhammar, L. Hafstrom, P. Nygren, B. Glimelius SBU-group1 A systematic overview of chemotherapy effects in colorectal cancer Acta Oncol 40 2001 282 308 (Pubitemid 32588124)
6. L.B. Saltz, J.V. Cox, C. Blanke Irinotecan Study Group Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer N Engl J Med 343 2000 905 914
7. J.Y. Douillard, D. Cunningham, A. Roth Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multi-centre randomised trial Lancet 355 2000 1041 1047 (Pubitemid 30162806)
8. A. de Gramont, A. Figer, M. Seymour Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2000 2938 2947 (Pubitemid 30644117)
9. National Institute for Clinical Excellence Capecitabine for the treatment of advanced gastric cancer Technology Appraisal Guidance. 2010 (TA191) [Accessed August 10, 2011] http://www.nice.org.uk/nicemedia/live/13049/49875/ 49875.pdf
10. M. Jones, S. Hummel, N. Bansback A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer Health Technol Assess 5 2001 1 145
11. M. Seymour, T.S. Maughan, J.A. Ledermann Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial Lancet 370 2007 143 152 (Pubitemid 47042894)
12. K. Claxton, M.J. Sculpher, M.F. Drummond A rational framework for decision making by the National Institute for Clinical Excellence Lancet 360 2002 711 715 (Pubitemid 35232343)
13. A.H. Briggs, M.J. Sculpher, K. Claxton Decision modelling for health economic evaluation 2006 Oxford University Press Oxford
14. R. Brooks EuroQol: the current state of play Health Policy 37 1996 53 72 (Pubitemid 26191458)
15. M.J. Sculpher, K. Claxton, M.F. Drummond, C. McCabe Whither trial-based economic evaluation for health care decision making? Health Econ 15 2006 677 687 (Pubitemid 44057239)
16. National Institute for Health and Clinical Excellence (NICE) Guide to the methods of technology appraisal 2008 National Institute for Health and Clinical Excellence (NICE) London
17. M. Barbieri, N. Hawkins, M. Sculpher Who does the numbers? The role of third-party technology assessment to inform health systems' decision-making about the funding of health technologies Value Health 15 2008 677 687 7
18. F.A. Sonnenberg, J.R. Beck Markov models in medical decision making: a practical guide Med Decis Making 13 1993 322 338 (Pubitemid 24013155)
19. T.J. Iverson, T. Hickish, C. Schmitt Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU Euro J Cancer 35 1999 1796 1804 (Pubitemid 29512311)
20. British National Formulary British National Formulary 2010 British Medical Association and the Royal Pharmaceutical Society of Great Britain London
21. UK Department of Health Reference cost 2008/2009 2010 Department of Health London http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-111591 [Accessed June 2, 2011]
22. M. Johannensson, M.C. Weinstein On the decision rules of cost-effectiveness analysis J Health Econ 12 1993 459 467
23. E. Fenwick, K. Claxton, M. Sculpher Representing uncertainty: the role of cost-effectiveness acceptability curves Health Econ 10 2001 779 789
24. P. Congdon Bayesian Models for Categorical Data 2005 John Wiley and Sons Ltd. Chicester
25. D.J. Spiegelhalter, N.G. Best Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling Stat Med 22 2003 3687 3709 (Pubitemid 37483543)
26. A. Briggs, R. Goree, G. Blackhouse, B. O'Brien Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease Med Decis Making 33 2001 290 308
27. R Development Core Team (2011) R: A language and environment for statistical computing R Foundation for Statistical Computing, Vienna, Austria ISBN 3-900051-07-0 http://www.R-project.org [Accessed August 10, 2011]
28. D.J. Lunn, T. Thomas, N. Best, D.J. Spiegelhalter WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility Stat Comput 10 2000 325 337
29. M. Koopman, N.F. Antonini, J. Douma Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial Lancet 370 2007 135 142 (Pubitemid 47042893)
30. D. Cunningham, B. Sirohi, A. Pluzanska Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer Ann Oncol 20 2009 244 250
31. C. Tournigand, T. Andre, E. Achille FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomised GERCOR study J Clin Oncol 22 2004 229 237 (Pubitemid 41095086)
32. O. Bouch, M. Castaing, P.L. Etienne Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000-05): preliminary results J Clin Oncol 25 Suppl. 2007 abstr 4069
33. M.T. Seymour, T.S. Maughan, H.S. Wasan Capecitabine and oxaliplatin in elderly and/or frail patients with metastatic colorectal cancer: The FOCUS2 trial J Clin Oncol 25 Suppl. 2007 abstr 9030
34. M.T. Seymour, C.J. Punt Sequential chemotherapy for advanced colorectal cancer: should we ever start with a single cytotoxic agent? Curr Colorectal Cancer Rep 4 2008 130 138
35. V. Golfinopoulos, G. Salanti, N. Pavlidis, J.P. Ioannidis Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis Lancet Oncol 8 2007 898 911 (Pubitemid 47488054)
36. UK Clinical Research Network A study to determine the feasibility of molecular selection of therapy using KRAS, BRAF and topo-1 in patients with metastatic or locally advanced colorectal cancer [database on the Internet] Portfolio Database http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID= 6445 2008 [Accessed August 10, 2011]
37. National Institute for Clinical Excellence Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer Technology Appraisal Guidance 33 TA118 2007
38. National Institute for Clinical Excellence Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (review) Technology Appraisal Guidance 33 TA118 2009 http://www.nice.org.uk/nicemedia/pdf/TA118Guidance.pdf [Accessed August 10, 2011]
39. L. Saltz Current role of bevacizumab in colorectal cancer Clin Adv Hematol Oncol 7 2009 375 376
40. L.B. Saltz, S. Clarke, E. Diaz-Rubio Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2008 2013 2019
41. R. Adams, A. Meade, H. Wasan Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial Expert Rev Anticancer Ther 8 2008 1237 1245
42. ClinicalTrial.gov FLOX + cetuximab (erbitux) for patients with metastatic colorectal cancer and wild type K-RAS tumor [database on the Internet] http://clinicaltrials.gov/ct2/show/NCT00660582 [Accessed August 10, 2011]
43. D. Hind, P. Tappenden, I. Tumur The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation Health Technol Assess 12 2008 iiiix, xi162
44. M. Seymour Fluorouracil, oxaliplatin and CPT-11 (irinotecan), use and sequencing (MRC FOCUS): a 2135- patient randomized trial in advanced colorectal cancer (ACRC) J Clin Oncol 23 2005 3518
45. E. Van Cutsem, G.H. Blijham Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure of first-line 5-fluorouracil Semin Oncol 26 1999 13 20 (Pubitemid 29174245)
46. C.H. Jackson, N.G. Best, S. Richardson Bayesian graphical models for regression on multiple data sets with different variables Biostatistics 10 2009 335 351